Skip to search formSkip to main contentSkip to account menu

Gemtuzumab ozogamicin

Known as: Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, gemtuzumab-ozogamicin, hP67.6-Calicheamicin 
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody… 
National Institutes of Health

Related topics

Related topics

8 relations
Acute myelomonocytic leukemiaDrug AllergyNCIt Antineoplastic Agent TerminologyPregnancy

Narrower (1)

CMA 676

Broader (1)

gemtuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials
Introduction: Downregulation or loss of B-cell ALL surface antigens (most notably CD19) in patients with acute lymphoblastic… 
2013
2013
Why is it so difficult to use gemtuzumab ozogamicin?
In this issue of Blood, Petersdorf et al report negative results of the phase 3 study designed by the Southwest Oncology Group… 
2012
2012
Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Gemtuzumab ozogamicin (GO; Mylotarg) is a drug–monoclonal antibody conjugate that delivers the cytotoxic agent chalicheamicin to… 
2012
2012
Minimal Residual Disease Assessed by WT1 Expression and NPM1 Mutations Specific RQ-PCR Assays Identifies Patients with Distinct Outcomes in the ALFA 0701 Trial and Is Decreased by Treatment with…
Abstract 659 Background: NPM1 mutations and WT1 expression are frequently identified in acute myeloid leukemia (AML). Both… 
Review
2011
Review
2011
Open access consortium
volume 29 number 4 april 2011 nature biotechnology Another cancer-killing conjugate is ImmunoGen’s IMGN901 (lorvotuzumab… 
Review
2010
Review
2010
Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML).
6552 Background: To compare survival outcomes among patients (pts) with CBF-AML treated with a regimen of fludarabine, cytarabine… 
2005
2005
A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia
et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid… 
Highly Cited
2004
Highly Cited
2004
Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure.
Gemtuzumab ozogamicin (GO; Mylotarg; Wyeth, PA) is a humanized anti-CD33 antibody conjugated to the cytotoxic agent calicheamicin… 
2004
2004
A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia.
2002
2002
Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin to patients < 60 years old with untreated…
Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)